U.S. FDA approves Krystal Biotech ' s skin-disorder gene therapy

The U.S. Food and Drug Administration on Friday approved Krystal Biotech Inc's (KRYS.O) first-of-its kind topical gene therapy for patients with a genetic skin disorder, sending its shares up 7% in afternoon trading. Patients with the rare dystrophic epidermolysis bullosa disorder suffer from open…#krystalbiotechinc #vyjuvek #krystalbiotech #krishkrishnan #fda #krishnan #krystal #bengaluru
Source: Reuters: Health - Category: Consumer Health News Source Type: news